| ID Source | ID |
|---|---|
| PubMed CID | 72131 |
| CHEMBL ID | 148824 |
| CHEBI ID | 35633 |
| SCHEMBL ID | 571103 |
| MeSH ID | M0059750 |
| Synonym |
|---|
| MLS002153893 , |
| smr001233242 |
| BRD-K37282009-001-02-3 |
| BRD-K37282009-002-03-9 |
| NSC95096 , |
| yohimbic acid |
| KBIO1_001251 |
| DIVK1C_006307 |
| CHEBI:35633 , |
| 17alpha-hydroxyyohimban-16alpha-carboxylic acid |
| yohimbinsaeure |
| SPECTRUM5_000725 |
| BPBIO1_000484 |
| SPECTRUM_001515 |
| SPECTRUM4_001955 |
| BSPBIO_000440 |
| 522-87-2 |
| PRESTWICK2_000590 |
| PRESTWICK3_000590 |
| yohimbinic acid |
| yohimban-16-carboxylic acid, (16.alpha.,17.alpha.)- |
| nsc-95096 |
| BSPBIO_002854 |
| KBIOSS_001995 |
| KBIO2_007131 |
| KBIO2_004563 |
| KBIO2_001995 |
| KBIOGR_002393 |
| KBIO3_002074 |
| SPECPLUS_000211 |
| PRESTWICK1_000590 |
| SPBIO_002659 |
| SPECTRUM3_001117 |
| SPECTRUM2_000451 |
| SPBIO_000522 |
| PRESTWICK0_000590 |
| CHEMBL148824 , |
| AKOS015955772 |
| CCG-38693 |
| nsc 95096 |
| einecs 208-337-7 |
| unii-35fav1eveg |
| yohimbic acid [inn] |
| acide yohimbique |
| acidum yohimbicum [inn-latin] |
| 17alpha-hydroxy-3alpha,15alpha,20beta-yohimban-16alpha-carbonsaeure |
| 35fav1eveg , |
| acide yohimbique [inn-french] |
| acidum yohimbicum |
| acido yohimbico [inn-spanish] |
| yohimban-16-carboxylic acid, 17-hydroxy-, (16alpha,17alpha)- |
| bdbm95054 |
| cid_6419962 |
| (1s,15r,18s,19r,20s)-18-oxidanyl-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid;hydrate |
| SCHEMBL571103 |
| yohimbic acid [who-dd] |
| DTXSID4048563 |
| (1r,2s,4ar,13bs,14as)-2-hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid |
| mfcd00167087 |
| (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid |
| NS-05570 |
| (1s,15r,18s,19r,20s)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0(2),(1)?.0?,?.0(1)?,(2)?]henicosa-2(10),4(9),5,7-tetraene-19-carboxylic acid |
| NCGC00178432-04 |
| (1s,15r,18s,19r,20s)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4(9),5,7-tetraene-19-carboxylic acid |
| Q27116536 |
| mfcd00005094 |
| (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid |
| (1s,15r,18s,19r,20s)-18-hydroxy-3,11,12,13,14,15,16,17,18,19,20,21-dodecahydro-1h-yohimban-13-ium-19-carboxylate |
| HY-121936 |
| EN300-302966 |
| CS-0083713 |
| yohimbineacid |
| (1r,2s,4ar,13bs,14as)-2-hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroisoquino[3,2-a]beta-carboline-1-carboxylic acid |
| Class | Description |
|---|---|
| yohimban alkaloid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||